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mating health costs associated with obesity 
will inform and strengthen the argument for 
effective intervention to reduce this burden in 
Jamaica.
With economic development comes the pu-
blic health transition mentioned above [1- 3]. 
Many mid- to low-income countries under-
going this transition will at the same time ma-
nifest significant burden from both groups of 
diseases. In such countries, as life expectan-
cies have increased, more persons survive, li-
ving long enough to be afflicted with CNCDs 
that result from unhealthy diets, obesity, low 
levels of physical activity as well as other 
risk factors. At the same time, segments of 
IntroductIon
The prevalence of obesity in Jamaica has 
been increasing over the last fifty years re-
sulting in the main public health concern 
changing from a high prevalence of undernu-
trition and infectious diseases to a high pre-
valence of obesity and chronic non-commu-
nicable diseases (CNCDs). Obesity is known 
to be associated with several chronic diseases 
(including diabetes, hypertension and their 
sequelae) and early mortality. As a result, 
obesity and its associated diseases are likely 
to contribute significantly to health care costs 
burden in the Jamaican society due to increa-
sed morbidity and premature mortality. Esti-
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AbstrAct
OBJECTIVE: To estimate the economic cost of Chronic Non-Communicable Diseases (CNCDs) and the portion attribut-
able to obesity among patients in Jamaica.
METHODS: The cost-of-illness approach was used to estimate the cost of care in a hospital setting in Jamaica for type 2 
diabetes mellitus, hypertension, coronary heart disease, stroke, gallbladder disease, breast cancer, colon cancer, osteoarthri-
tis, and high cholesterol. Cost and service utilization data were collected from the hospital records of all patients with these 
diseases who visited the University Hospital of the West Indies (UHWI) during 2006. Patients were included in the study 
if they were between15 and 74 years of age and if female, were not pregnant during that year. Costs were categorized as 
direct or indirect. Direct costs included costs for prescription drugs, consultation visits (emergency and clinic visits), hospi-
talizations, allied health services, diagnostic and treatment procedures. Indirect costs included costs attributed to premature 
mortality, disability (permanent and temporary), and absenteeism. Indirect costs were discounted at 3% rate.
RESULTS: The sample consisted of 554 patients (40%) males (60%) females. The economic burden of the nine diseases 
was estimated at US$ 5,672,618 (males 37%; females 63%) and the portion attributable to obesity amounted to US$ 
1,157,173 (males 23%; females 77%). Total direct cost was estimated at US$ 3,740,377 with female patients accounting 
for 69.9% of this cost. Total indirect cost was estimated at US$ 1,932,241 with female patients accounting for 50.6% of this 
cost. The greater cost among women was not found to be statistically significant. Overall, on a per capita basis, males and 
females accrued similar costs-of-illness (US$ 9,451.75 vs. US$ 10,758.18).
CONCLUSIONS: In a country with per capita GDP of less than US$ 5,300, a per capita annual cost of illness of US$ 
10,239 for CNCDs is excessive and has detrimental implications for the health and development of Jamaica. 
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the population are still dealing with the tradi-
tional risks to health including unsafe water, 
under-nutrition and poor sanitation [2-4].
Jamaica has been undergoing the epidemio-
logical transition described above [5]. More 
than half of Jamaicans are overweight or 
obese [5] and both overweight and obesity 
are associated with several comorbidities 
[6,7]. According to Bray et al. [8], there are 
two physiological categories into which each 
disease with an increased risk as a result of 
the presence of overweight can be classi-
fied. The first category of disabilities is due 
to the physical presence of corpulence. Psy-
chosocial function, osteoarthritis and sleep 
apnea belong in this category. The second 
category of disabilities results from the me-
tabolic changes associated with overweight 
(e.g., diabetes mellitus, gallbladder disease, 
hypertension, cardiovascular disease, and 
certain cancers [8]). Also the incidence of 
several chronic diseases increase with degree 
of overweight [6,7,9]. Several studies show 
an association between overweight/obesity 
and CNCDs, e.g., diabetes mellitus [10-16], 
gallbladder disease [17,18], hypertension 
[10,19-21], coronary heart disease [22-25], 
stroke [26-32], and serum triglyceride levels 
[33,34].
Seventy percent of Jamaican women and 
20% of Jamaican men have high waist cir-
cumferences (WC) [5]. Also, 70% of Jamai-
can women and 9% of Jamaican men have 
high waist-to-hip ratios (WHR) [5]. Both are 
associated with increased cardiovascular risk 
[22-24,35]. Therefore, estimating the impact 
of obesity is via the burden of chronic non-
communicable diseases for which obesity is a 
major risk factor is well-founded. Especially 
since seven of the 10 leading causes of mor-
tality in Jamaica in 1998 were CNCDs [36].
For Jamaica in 2001, the total economic bur-
den of diabetes and hypertension amounted 
to J$ 10.18 billion (US$ 221 million at 2001 
exchange rates) and J$ 12.26 billion (US$ 
266 million at 2001 exchange rates) respec-
tively [37]. Given that obesity is a risk factor 
for both diabetes and hypertension, obesity is 
therefore a significant burden on the Jamai-
can economy.
The foregoing suggests that CNCDs constitu-
te an important disease burden to the Jamai-
can Health Sector and significant economic 
burden to the country. This epidemiological/
economic transition is leading to increased 
prevalence of CNCDs, requiring more he-
alth care and increasing costs. These growing 
costs are unsustainable and if left unchecked 
could reverse health gains and hinder econo-
mic growth. To obtain a greater insight into 
this subject, a case study of the University 
Hospital of the West Indies (UHWI) was 
done. There are several studies that estima-
te the cost of obesity [38-40]. Those studies 
for the most part, used prevalence data, whi-
le this study estimated the economic burden 
of nine CNCDs using data from hospital re-
cords.
This study aimed to estimate the economic 
burden of obesity and related chronic non-
communicable diseases among patients in 
Jamaica. Health care in Jamaica is provided 
through a combination of public, private and 
quasi-public sector hospitals and healthcare 
facilities. The UHWI is the largest hospital 
in Jamaica and serves as a regional referral 
hospital. Therefore, patients who visited the 
UHWI during 2006 were deemed most su-
itable for this study. Data from hospital re-
cords of patients who visited UHWI during 
2006 were analysed to estimate the economic 
burden of CNCDs. These estimations would 
provide important information for policy de-
velopment, program planning and resource 
allocation in relation to CNCD management. 
In addition, the knowledge obtained will be 
useful as a benchmark of the economic cost of 
obesity in Jamaica and as a point of reference 
in the estimation of the economic burden of 
disease. Actual use of medical services were 
used to estimate the monetary value of that 
burden in order to strengthen our argument 
for intervention and guide policy makers.
Methods
Design of the study
This is a prevalence-based cost-of-illness 
evaluation study using a survey of patient 
records and data from secondary sources. 
Primary data including cost and service uti-
lization data were collected from the hospital 
records of patients. Secondary data inclu-
ded prevalence data from local [5] and other 
sources [6,41] which were used to calculate 
the population attributable risk of obesity.
setting
Study subjects included all adult patients 
who visited the University Hospital of the 
West Indies as a result of type 2 diabetes, 
hypertension, coronary heart disease, stro-
ke, gallbladder disease, breast cancer, colon 
cancer, osteoarthritis, and high cholesterol 
during 2006, and who were 15-74 years old 
and if female, did not give birth during the 
reference year. The age-range of 15-74 years 
was chosen because it represents approxima-
tely 70% of the Jamaican population [42] and 
captures predominantly the economically ac-
tive population.
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Medical records were used to calculate ac-
tual costs of medical care to each patient as 
a result of type 2 diabetes, hypertension, co-
ronary heart disease, stroke, gallbladder dise-
ase, breast cancer, colon cancer, osteoarthri-
tis, and high cholesterol. The human capital 
approach was used to calculate the cost-of-
illness due to mortality and morbidity. Cost-
of-illness calculations were divided into two 
types: direct costs and indirect costs. Direct 
costs included costs of drugs, consultations 
and hospitalizations, while indirect costs in-
cluded costs attributed to morbidity, and pre-
mature mortality.
Direct costs
Drugs
The hospital records were used to generate 
the list of drugs prescribed to patients to ma-
nage their conditions. The usual customary 
and reasonable (UCR) costs suggested by 
pharmacies were then applied to calculate 
costs of drugs needed for each disease condi-
tion by multiplying the unit cost of each drug 
prescribed by the dosage. This gave an esti-
mate of the amount spent on each drug for the 
year. The total amount spent on drugs in 2006 
was determined by summing these products 
across all drugs.
Consultations
Consultation costs were calculated from am-
bulatory patients whether or not they were 
hospitalized at any point throughout the year. 
The total number of visits was multiplied by 
the cost of a clinic visit to arrive at the cost of 
consultation for each patient. The addition of 
the individual costs of consultation represen-
ted the total costs of consultation.
Hospitalizations
Hospitalization costs consisted of charges 
for medications used during hospitalization 
and investigative and therapeutic procedures 
done. These charges were retrieved from the 
medical records of patients and summed up 
to get the total cost of hospitalization in 2006.
Allied Health Services, diagnostic 
and treatment procedures
Records of allied health services, medical 
tests and other laboratory procedures, and 
treatment procedures carried as outpatient 
services were used to ascertain the types of 
services utilized and procedures done and 
their frequencies. The unit cost of each servi-
ce/procedure for 2006 was obtained from the 
hospital’s assessment office. The total cost 
of each service/procedure was determined 
as the product of its unit cost and the total 
number of times the service/procedure was 
done in 2006. The total costs of the allied he-
alth services, diagnostic procedures, and tre-
atment procedures for 2006 were determined 
by summing the cost of individual items in 
each category.
indirect costs
Premature mortality
Data on mortality resulting from each comor-
bidity were obtained from the hospital data-
base and the number of Years of Productive 
Life Lost in employed patients due to prema-
ture mortality (YPLLM) associated with each 
comorbidity was calculated based on the life 
expectancy for males and females in Jamaica 
as reported by the World Health Organization 
(WHO). A 3% discount rate was applied to the 
YPLL to convert future earnings to current va-
lue [43,44]. The cost was then calculated by 
multiplying YPLL by annual per capita GNP.
Where N = number of deaths; L = standard life expectancy 
at age of death (years), and r = discount rate
Disability
Permanent Disability
The number of years lost due to permanent 
disability before the age of 65 years was also 
calculated. This is the number of YPLL
D
.
The patients were divided into age groups 
and YPLL
D
 due to permanent disability was 
calculated by multiplying the number of pa-
tients in each age group by the difference 
between the age limit of 65 years and the me-
dian of the age group as shown in the equa-
tion below [45]:
Where l = lower age limit established (median age), 
L = upper age limit established (65 years), i = median age 
at beginning of permanent disability, and di = number of 
patients with permanent disability at age i.
A 3% discount rate was then applied to cal-
culate the number of discounted YPLL due to 
permanent disability. The cost of permanent 
disability was then estimated by multiplying 
the annual per capita GNP by YPLL
D
.
Temporary Disability
The number of years lost due to temporary 
disability (YPLLT) before the age of 65 years 
was calculated from the number of disability 
days for patients who did not have a perma-
nent disability. A 3% discount rate was then 
applied to calculate the number of discounted 
YPLLT. The cost of temporary disability was 
then estimated by multiplying the annual per 
capita GNP by the number of YPLLT. Where 
the period of temporary disability was less 
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than one year, discounting did not apply. In 
such cases, the fraction of year of disability 
was simply calculated by dividing the num-
ber of disability days by 365.
Absenteeism
The number of absent days for employed pa-
tients was estimated as the sum of the num-
ber of days spent in consultation, in hospita-
lization and on sick leave from work. Thus, 
sick leave days were underestimated as this 
information was not always recorded in the 
clinical files. Lost salaries were then estima-
ted. The first step was separating the emplo-
yed patients according to the International 
Standard Classification of Occupations 2008 
(ISCO-08) [46]. The major groups of the 
classification were: managers, professionals, 
technicians and associate professionals, cle-
rical support workers, service and sales wor-
kers, skilled agricultural, forestry and fishery 
workers, craft and related trades workers, 
plant and machine operators, and assemblers, 
elementary occupations, and armed forces 
occupations [46]. The next step was to obtain 
the daily salaries of each category from na-
tional databases [47,48]. The salaries were 
then converted to U.S. dollars at 2006 US 
average annual rate of exchange. The cost-
of-illness due to absenteeism was calculated 
as the product of the number of days absent 
and the daily salaries [49].
Cost of obesity
The economic burden of obesity was then 
estimated from the calculated direct and in-
direct costs of type 2 diabetes, hypertension, 
coronary heart disease, stroke, gallbladder 
disease, breast cancer, colon cancer, osteo-
arthritis, and high cholesterol. The analysis 
of the proportion of the cost of each case 
which was attributable to obesity was based 
on the population attributable risk of obesity. 
The population attributable risk (PAR) is also 
referred to as the “etiologic fraction” or “po-
pulation attributable fraction”. It is a measure 
of the proportion of cases of a given disease 
(e.g., type 2 diabetes) that is due to a risk fac-
tor of interest (e.g., obesity). The population 
attributable risk of obesity was applied to the 
direct and indirect costs of each of the dise-
ase. The sum of the costs gave an estimate 
of the economic burden of obesity. There are 
several studies that support the use of PAR 
for the estimation of the fraction of a disease 
that is attributable to obesity [50-53].
Where PAR = population attributable risk, RR = relative risk 
(estimated by the odds ratio, OR), and P = prevalence rate 
of disease/mortality.
However in order to estimate the PAR, the 
relative risk of each obesity comorbidity was 
obtained from other studies.
Since relative risks were not available for Ja-
maica on all of the comorbidities of interest 
(except for diabetes mellitus, hypertension 
and high cholesterol), relative risks for the 
remaining comorbidities were obtained from 
studies from other countries. In order to deci-
de which source(s) of relative risks to use, the 
relative risks obtained were compared with 
those available for Jamaica. The countries for 
which relative risks could be found that were 
comparable with those available for Jamaica 
were used as the sources for the other relative 
risk values (Table I).
The PAR for obesity and the 95% confidence 
intervals (CIs) were then computed for each 
comorbidity. The PAR for each of the 9 co-
morbidities studied was multiplied by the 
cost of the corresponding comorbidity and 
then summed to represent the corresponding 
estimate of the cost of obesity. A sensitivity 
analysis was also done on both the estimated 
costs and the PARs to provide a range of va-
lues for the cost estimates.
sensitivity analysis
One-way sensitivity analyses was performed 
to assess the robustness of the total cost esti-
mates. In a one-way sensitivity analysis, the 
value of one variable is changed at a time in 
the estimation of cost, and the impact that the 
change has on the results examined. In this 
study, the cost of illness was estimated at 
the 3% discount rate. It was then analyzed at 
95% and 97.5% confidence intervals for the 
population attributable risks for obesity.
results
All 554 patients (except females who gave 
birth during 2006) between the ages of 15-74 
years of age who visited the hospital during 
2006 for the diseases being studied were in-
cluded in the study. The mean age was 56.9 
years. Of the patients studied, 220 (40%) 
were males and 334 (60%) were females.
Direct costs
Drugs
The total cost of prescription drugs was US$ 
2,245,245.10, averaging US$ 4,052.79 per 
patient during 2006. The greatest proportion 
of the payment was on drugs for the manage-
ment of diabetes mellitus (US$ 1,531,885.30; 
68.2%), followed by coronary heart disease 
(US$ 296,634.72; 13.2%), hypertension (US$ 
186,821.16; 8.3%) and breast cancer (US$ 
75,246.04; 3.4%). The least amount spent on 
drugs was for gallbladder disease (US$ 6.90) 
Disease
rr (95%Ci) Par [% (95%Ci)] Par [% (97.5%Ci)]
Males Females Males Females Males Females
DM [7] 2.05 
(1.20-3.49)
2.14 
(1.32-3.47)
0.11 
(0.0687-0.151)
0.30 
(0.259-0.341)
0.11 
(0.0625-0.157)
0.30 
(0.253-0.347)
hTn [7] 2.36 
(1.47-3.78)
2.76 
(1.85-4.11)
0.14 
(0.0989-0.181)
0.40 
(0.359-0.441)
0.14 
(0.0928-0.187)
0.40 
(0.353-0.447)
ChD [43] 1.40 
(1.17-1.68)
1.32 
(1.07-1.62)
0.05 
(8.40 x10-3 -0.0916)
0.11 
(0.0684-0.152)
0.05 
(2.24x10-3 -0.0978)
0.11 
(0.0622-0.158)
s [8]
 • Overweight 1.23 
(1.13-1.34)
1.15 
(1.00-1.32)
0.03 
(0.0116-0.0716)
0.05 
(0.0488-0.0512)
0.03 
(0.0177-0.0777)
0.05 
(0.0486-0.0514)
 • Obesity 1.51 
(1.33-1.72)
1.49 
(1.27-1.74)
0.06 
(0.0184-0.1016)
0.16 
(0.118-0.202)
0.06 
(0.0123-0.1077)
0.16 
(0.112-0.2077)
gD [8]
 • Overweight 1.09 
(0.87-1.37)
1.44 
(1.05-1.98)
0.01 
(-0.0292-0.0492)
0.14 
(0.100-0.179)
0.01 
(-0.0349-0.0549)
0.14 
(0.0951-0.185)
 • Obesity 1.43 
(1.04-1.96)
2.32 
(1.17-4.57)
0.05 
(0.01084-0.0892)
0.33 
(0.291-0.369)
0.05 
(5.05 x10-3 -0.0949)
0.33 
(0.285-0.375)
BC [8]
Overweight - 1.08 
(1.03-1.14)
0.03 
(0.0265-0.0335)
0.03 
(0.0259-0.0341)
Obesity - 1.13 
(1.05-1.22)
0.05 
(0.0333-0.133)
0.05 
(0.0456-0.146)
CC [8]
 • Overweight 1.51 
(1.37-1.67)
1.45 
(1.30-1.62)
0.06 
(0.0200-0.100)
0.15 
(0.110-0.190)
0.06 
(0.0141-0.1059)
0.15 
(0.1041-0.196)
 • Obesity 1.95 
(1.59-2.39)
1.66 
(1.52-1.81)
0.10 
(0.0600-0.140)
0.20 
(0.160-0.240)
0.10 
(0.0541-0.146)
0.20 
(0.154-0.246)
Oa [8]
Overweight 2.76 
(2.05-3.70)
1.80 
(1.75-1.85)
0.17 
(0.144-0.196)
0.23 
(0.204-0.256)
0.17 
(0.140-0.200)
0.23 
(0.200-0.260)
Obesity 4.20 
(2.76-6.41)
1.96 
(1.88-2.04)
0.28 
(0.254-0.306)
0.27 
(0.254-0.296)
0.28 
(0.250-0.310)
0.27 
(0.240-0.300)
hC [7] 2.89 
(2.04-4.10)
3.57 
(1.91-6.68)
0.18 
(0.139-0.221)
0.49 
(0.449-0.531)
0.18 
(0.133-0.227)
0.49 
(0.443-0.537)
Obesity 
prevalence 
(%) [7]
12 38 - - - -
Table i. Relative Risk (RR) due to obesity and Population Attributable Risk (PAR) due to obesity for the diseases studied
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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for diabetes mellitus (89%), hypertension 
(66%), stroke (64%), coronary heart disease 
(61%), and osteoarthritis (49%). The diseases 
for which drugs contributed the least towards 
total overall treatment were colon cancer and 
gallbladder disease at 6% and 0.1% respecti-
vely (Table III).
Consultations
The total cost of consultations (out-patient + 
emergency visits) for 2006 for these patients 
was US$23,811.20. Females accounted for 
72.6% of this cost, however, women were 
not found to have statistically higher con-
sultations costs (P-value = 0.17; CI = 95%) 
(Table II). Breast cancer, diabetes mellitus, 
hypertension, and coronary heart disease ac-
which accounted for < 0.01% of the total 
amount spent on drugs by patients (Table II). 
Women accounted for about 62% of the ove-
rall cost of drug therapy. This amounted to 
US$ 1,388,280.79. Being a woman was not 
found to be statistically associated with grea-
ter drug costs (p = 0.63; CI = 95%). The ave-
rage costs per males and females were US$ 
3,895.29 and US$ 4,156.53 respectively.
Payment on drugs accounted for a major 
proportion of the cost of treatment. For high 
cholesterol, approximately 100% of the to-
tal expenditure for treatment was on drugs. 
In addition, the proportion of the cost of tre-
atment that was due to drug cost expenditure 
was at least about half of the cost or greater 
However in order to estimate the PAR, the 
relative risk of each obesity comorbidity was 
obtained from other studies.
Since relative risks were not available for Ja-
maica on all of the comorbidities of interest 
(except for diabetes mellitus, hypertension 
and high cholesterol), relative risks for the 
remaining comorbidities were obtained from 
studies from other countries. In order to deci-
de which source(s) of relative risks to use, the 
relative risks obtained were compared with 
those available for Jamaica. The countries for 
which relative risks could be found that were 
comparable with those available for Jamaica 
were used as the sources for the other relative 
risk values (Table I).
The PAR for obesity and the 95% confidence 
intervals (CIs) were then computed for each 
comorbidity. The PAR for each of the 9 co-
morbidities studied was multiplied by the 
cost of the corresponding comorbidity and 
then summed to represent the corresponding 
estimate of the cost of obesity. A sensitivity 
analysis was also done on both the estimated 
costs and the PARs to provide a range of va-
lues for the cost estimates.
sensitivity analysis
One-way sensitivity analyses was performed 
to assess the robustness of the total cost esti-
mates. In a one-way sensitivity analysis, the 
value of one variable is changed at a time in 
the estimation of cost, and the impact that the 
change has on the results examined. In this 
study, the cost of illness was estimated at 
the 3% discount rate. It was then analyzed at 
95% and 97.5% confidence intervals for the 
population attributable risks for obesity.
results
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were males and 334 (60%) were females.
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68.2%), followed by coronary heart disease 
(US$ 296,634.72; 13.2%), hypertension (US$ 
186,821.16; 8.3%) and breast cancer (US$ 
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(0.01084-0.0892)
0.33 
(0.291-0.369)
0.05 
(5.05 x10-3 -0.0949)
0.33 
(0.285-0.375)
BC [8]
Overweight - 1.08 
(1.03-1.14)
0.03 
(0.0265-0.0335)
0.03 
(0.0259-0.0341)
Obesity - 1.13 
(1.05-1.22)
0.05 
(0.0333-0.133)
0.05 
(0.0456-0.146)
CC [8]
 • Overweight 1.51 
(1.37-1.67)
1.45 
(1.30-1.62)
0.06 
(0.0200-0.100)
0.15 
(0.110-0.190)
0.06 
(0.0141-0.1059)
0.15 
(0.1041-0.196)
 • Obesity 1.95 
(1.59-2.39)
1.66 
(1.52-1.81)
0.10 
(0.0600-0.140)
0.20 
(0.160-0.240)
0.10 
(0.0541-0.146)
0.20 
(0.154-0.246)
Oa [8]
Overweight 2.76 
(2.05-3.70)
1.80 
(1.75-1.85)
0.17 
(0.144-0.196)
0.23 
(0.204-0.256)
0.17 
(0.140-0.200)
0.23 
(0.200-0.260)
Obesity 4.20 
(2.76-6.41)
1.96 
(1.88-2.04)
0.28 
(0.254-0.306)
0.27 
(0.254-0.296)
0.28 
(0.250-0.310)
0.27 
(0.240-0.300)
hC [7] 2.89 
(2.04-4.10)
3.57 
(1.91-6.68)
0.18 
(0.139-0.221)
0.49 
(0.449-0.531)
0.18 
(0.133-0.227)
0.49 
(0.443-0.537)
Obesity 
prevalence 
(%) [7]
12 38 - - - -
Table i. Relative Risk (RR) due to obesity and Population Attributable Risk (PAR) due to obesity for the diseases studied
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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Cost of care of chronic non-communicable diseases in Jamaican patients: the role of obesity
counted for the greater proportion of the ove-
rall consultation cost: US$ 6,920.13 (29.1%); 
US$6,218.55 (26.1%); US$ 4,188.22 (17.6%) 
and US$ 4,007.51 (16.8%) respectively (Ta-
ble II).
Prescription 
drugs (Us$)
Consultation 
(Us$)
Drugs used 
during hospita‑
lization (Us$)
allied health 
services 
(Us$)
Diagnostic 
services 
(Us$)
Treatment 
services 
(Us$)
Total direct cost 
[Us$ (%)]
DM
 • Males 575,149.75 2,636.67 6,673.64 242.83 10,323.33 47,927.19 642,953.41 (37.5)
 • Females 956,735.55 3,581.88 12,634.53 537.25 35,221.25 62,950.40 1,071,660.86 (62.5)
 • Total 1,531,885.30 6,218.55 19,308.17 780.08 45,544.58 110,877.59 1,714,614.27 (100)
hTn
 • Males 87,293.87 1,604.09 1,783.50 7,719.62 24,220.18 6,613.51 129,234.77 (45.7)
 • Female 99,527.29 2,584.13 2,193.63 801.41 43,242.60 5,065.25 153,414.31 (54.3)
 • Total 186,821.16 4,188.22 3,977.13 8,521.03 67,462.78 11,678.76 282,649.08 (100)
ChD
 • Males 135,802.18 1,518.85 2,778.74 443.18 28,166.29 84,743.50 253,452.74 (52.1)
 • Females 160,832.54 2,488.66 4,738.14 270.16 40,655.74 24,337.84 233,323.08 (47.9)
 • Total 296,634.72 4,007.51 7,516.88 713.34 68,822.03 109,081.34 486,775.82 (100)
s
 • Males 26,079.27 393.10 851.76 267.09 9,876.49 601.10 38,068.81 (46.2)
 • Females 26,546.44 521.08 2,212.09 421.87 14,361.64 337.00 44,400.12 (53.8)
 • Total 52,625.71 914.18 3,063.85 688.96 24,238.13 938.10 82,468.93 (100)
gD
 • Males 0.00 42.48 0.00 0.00 721.77 0.00 764.25 (7.1)
 • Females 6.90 244.53 407.60 18.21 1,838.51 7,554.34 10,070.09 (92.9)
 • Total 6.90 287.01 407.60 18.21 2,560.28 7,554.34 10,834.34 (100)
BC
 • Males 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (0)
 • Females 75,246.04 6,920.13 2,595.82 124.44 96,134.23 771,977.99 952,998.65 (100)
 • Total 75,246.04 6,920.13 2,595.82 124.44 96,134.23 771,977.99 952,998.65 (100)
CC
 • Males 66.12 180.75 173.11 27.32 3,840.33 14,875.73 19,163.36 (33.2)
 • Females 3,577.98 372.01 329.68 6.07 3,983.75 30,366.08 38,635.57 (66.8)
 • Total 3,644.10 552.76 502.79 33.39 7,824.08 45,241.81 57,798.93 (100)
Oa
 • Males 11,799.03 127.24 0.18 36.42 165.41 7,554.34 19,682.62 (18.8)
 • Females 39,256.69 542.45 88.06 133.54 894.83 44,237.91 85,153.48 (81.2)
 • Total 51,055.72 669.69 88.24 169.96 1,060.24 51,792.25 104,836.10 (100)
hC
 • Males 20,774.09 31.89 7.12 0.00 0.00 0.00 20,813.10 (43.9)
 • Females 26,551.36 21.26 0.00 0.00 15.18 0.00 26,587.80 (56.1)
 • Total 47,325.45 53.15 7.12 0.00 15.18 0.00 47,400.90 (100)
economic burden
 • Males 856,964.31 6,535.07 12,268.05 8,736.46 77,313.80 162,315.37 1,124,133.06 (30.1)
 • Females 1,388,280.79 17,276.13 25,199.55 2,312.95 236,347.73 946,826.81 2,616,243.96 (69.9)
 • Total 2,245,245.10 23,811.20 37,467.60 11,049.41 313,661.53 1,109,142.18 3,740,377.02 (100)
Table ii. Breakdown of the total direct costs of the diseases studied by gender (US$) 
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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Females accounted for 61.3% of the cost of 
consultations when the cost of breast cancer 
was removed from the results. Again, women 
were not found to have statistically greater 
consultations costs even without the inclusion 
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C. M. Fray-Aiken, R. J. Wilks, A. O. Abdulkadri, A. M. McCaw-Binns
counted for the greater proportion of the ove-
rall consultation cost: US$ 6,920.13 (29.1%); 
US$6,218.55 (26.1%); US$ 4,188.22 (17.6%) 
and US$ 4,007.51 (16.8%) respectively (Ta-
ble II).
Prescription 
drugs (Us$)
Consultation 
(Us$)
Drugs used 
during hospita‑
lization (Us$)
allied health 
services 
(Us$)
Diagnostic 
services 
(Us$)
Treatment 
services 
(Us$)
Total direct cost 
[Us$ (%)]
DM
 • Males 575,149.75 2,636.67 6,673.64 242.83 10,323.33 47,927.19 642,953.41 (37.5)
 • Females 956,735.55 3,581.88 12,634.53 537.25 35,221.25 62,950.40 1,071,660.86 (62.5)
 • Total 1,531,885.30 6,218.55 19,308.17 780.08 45,544.58 110,877.59 1,714,614.27 (100)
hTn
 • Males 87,293.87 1,604.09 1,783.50 7,719.62 24,220.18 6,613.51 129,234.77 (45.7)
 • Female 99,527.29 2,584.13 2,193.63 801.41 43,242.60 5,065.25 153,414.31 (54.3)
 • Total 186,821.16 4,188.22 3,977.13 8,521.03 67,462.78 11,678.76 282,649.08 (100)
ChD
 • Males 135,802.18 1,518.85 2,778.74 443.18 28,166.29 84,743.50 253,452.74 (52.1)
 • Females 160,832.54 2,488.66 4,738.14 270.16 40,655.74 24,337.84 233,323.08 (47.9)
 • Total 296,634.72 4,007.51 7,516.88 713.34 68,822.03 109,081.34 486,775.82 (100)
s
 • Males 26,079.27 393.10 851.76 267.09 9,876.49 601.10 38,068.81 (46.2)
 • Females 26,546.44 521.08 2,212.09 421.87 14,361.64 337.00 44,400.12 (53.8)
 • Total 52,625.71 914.18 3,063.85 688.96 24,238.13 938.10 82,468.93 (100)
gD
 • Males 0.00 42.48 0.00 0.00 721.77 0.00 764.25 (7.1)
 • Females 6.90 244.53 407.60 18.21 1,838.51 7,554.34 10,070.09 (92.9)
 • Total 6.90 287.01 407.60 18.21 2,560.28 7,554.34 10,834.34 (100)
BC
 • Males 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (0)
 • Females 75,246.04 6,920.13 2,595.82 124.44 96,134.23 771,977.99 952,998.65 (100)
 • Total 75,246.04 6,920.13 2,595.82 124.44 96,134.23 771,977.99 952,998.65 (100)
CC
 • Males 66.12 180.75 173.11 27.32 3,840.33 14,875.73 19,163.36 (33.2)
 • Females 3,577.98 372.01 329.68 6.07 3,983.75 30,366.08 38,635.57 (66.8)
 • Total 3,644.10 552.76 502.79 33.39 7,824.08 45,241.81 57,798.93 (100)
Oa
 • Males 11,799.03 127.24 0.18 36.42 165.41 7,554.34 19,682.62 (18.8)
 • Females 39,256.69 542.45 88.06 133.54 894.83 44,237.91 85,153.48 (81.2)
 • Total 51,055.72 669.69 88.24 169.96 1,060.24 51,792.25 104,836.10 (100)
hC
 • Males 20,774.09 31.89 7.12 0.00 0.00 0.00 20,813.10 (43.9)
 • Females 26,551.36 21.26 0.00 0.00 15.18 0.00 26,587.80 (56.1)
 • Total 47,325.45 53.15 7.12 0.00 15.18 0.00 47,400.90 (100)
economic burden
 • Males 856,964.31 6,535.07 12,268.05 8,736.46 77,313.80 162,315.37 1,124,133.06 (30.1)
 • Females 1,388,280.79 17,276.13 25,199.55 2,312.95 236,347.73 946,826.81 2,616,243.96 (69.9)
 • Total 2,245,245.10 23,811.20 37,467.60 11,049.41 313,661.53 1,109,142.18 3,740,377.02 (100)
Table ii. Breakdown of the total direct costs of the diseases studied by gender (US$) 
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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of breast cancer cost (p = 0.44; CI = 95%). 
Outpatient consultations accounted for 75.8% 
of the overall cost of consultations (Table III).
Hospitalization
The greatest cost accrued during hospitaliza-
tions was for breast cancer at US$ 330,758.56, 
followed by coronary heart disease, diabetes 
mellitus, and hypertension at US$ 179,741.83; 
US$ 162,124.54, and US$ 79,712.36, respec-
tively (Table II). With respect to the procedu-
res and services used during hospitalization, 
the greatest contributors were treatment servi-
ces at US$ 542,288.19 and diagnostic proce-
dures at US$ 283,156.57 (Table III).
Allied health services
The total cost of allied health services (e.g., 
dietician visit and physiotherapy), was US$ 
11,049.41, which accounted for 0.1% of the 
overall cost, and 0.3% of the total direct cost. 
Most of the cost of these services (72%) 
accrued during consultation visits (US$ 
7,965.60), with the remaining services oc-
curring during hospitalization (Table II and 
III). Hypertension was responsible for the 
greatest cost for allied health services at US$ 
8,521.03. No allied health services were em-
ployed by patients who visited the hospital 
due to high cholesterol (Table II and III).
Amount spent on diagnostic 
and treatment services
The participants used several diagnostic ser-
vices during 2006 and spent a total of US$ 
313,661.53 (3% of total overall cost, 8% of 
total direct cost). The greatest costs accrued 
were for breast cancer, coronary heart disea-
se, hypertension and diabetes mellitus at US$ 
96,134.23, US$ 68,822.03, US$ 67,462.78, 
and US$ 42,239.03, respectively. High cho-
lesterol was responsible for the least cost 
accrued due to diagnostic services at US$ 
15.18 (Table II). Most (90.3%) of the cost 
of diagnostic procedures was accrued during 
hospitalization (Table III).
Treatment services accrued a cost of US$ 
1,109,142.18 (12% of total overall cost and 
30% of total direct cost). The greatest costs 
accrued were for breast cancer, diabetes mel-
litus, coronary heart disease, and colon can-
cer at US$ 771,977.99, US$ 110,877.59, US$ 
109,081.34, and US$ 45,241.81, respectively 
(Table II). Treatment services were divided 
almost equally between consultations and 
hospitalizations (51% and 49%, respectively) 
(Table III).
indirect costs
Premature mortality
The estimated cost of premature mortality 
was US$ 95,309.00. Although deaths occur-
red for both genders, this cost was estimated 
from the YPLL, and could only be compu-
ted for women because the mortality obser-
ved for males occurred beyond the age of 65 
years. The diseases responsible for this cost 
were breast cancer at US$ 72,355.00 (75.9% 
cost of premature mortality) and hyperten-
sion at US$ 22,954.00 (24.1% cost of prema-
ture mortality) (Table IV).
Permanent disability
The total discounted cost of permanent disa-
bility was based on 38 patients and accrued a 
cost of US$ 1,908,176.00 (28% of total cost 
and 81% of total indirect cost). The comorbi-
dities responsible for permanent disabilities 
were diabetes mellitus, hypertension, stro-
ke and osteoarthritis, accruing discounted 
costs of US$ 867,761.00, US$ 206,087.00, 
US$144,211.00, and US$ 349,799.00, re-
spectively (Table IV).
Cost of temporary disability
The total discounted cost of temporary di-
sability in patients under 65 years who were 
not permanently disabled amounted to US$ 
39,899.10 in lost productivity. Fifty-three 
percent of this loss was as a result of tempo-
rary disability in men. Temporary disability 
was responsible for 2% of the indirect cost 
and 0.7% of the total cost of the diseases stu-
died (Table IV).
Coronary heart diseases accrued the greatest 
cost due to temporary disability followed by 
diabetes, hypertension, and colon cancer at 
US$ 17,987.40 (45%), US$ 13,457.91 (34%), 
US$ 3,575.38 (9%), and US$ 2,859.76 (9%), 
respectively (Table IV).
Cost of absenteeism
The total cost of absentee days was US$ 
229,175.56. Women were responsible for 
55.5% of overall losses due to absenteeism. 
The diseases that contributed the most to this 
cost were diabetes mellitus, hypertension, 
breast cancer and coronary heart disease at 
US$ 70,505.28 (31%), US$ 54,819.30 (24%), 
US$ 40,174.64 (18%), and US$ 38,573.68 
(17%), respectively (Table IV).
Overall costs
The sum of the costs attributable to the di-
seases studied was US$ 5,672,617.68. The 
four main contributors were diabetes mellitus 
(47.0%), breast cancer (18.8%), hypertension 
(10.0%), and coronary heart disease (9.6%). 
Female patients were responsible for 63.3% 
of the overall costs attributable to the dise-
ases covered. However, being a woman was 
not found to be statistically associated with 
greater overall costs (p = 0.44; CI = 95%). 
Female patients also accrued more than half 
Disease
indirect cost (Us$)
Premature 
mortality
Permanent 
disability
Temporary 
disability
absenteeism Total [Us$ (%)]
DM
 • Males - 583,331.00 11,498.32 36,565.14 631,394.46 (66.3)
 • Females - 284,430.00 1,959.59 33,940.14 320,329.73 (33.7)
 • Total - 867,761.00 13,457.91 70,505.28 951,724.19 (100)
hTn
 • Males 0.00 65,369.00 1,922.30 28,447.05 95,738.35 (33.3)
 • Females 22,954.00 140,718.00 1,653.08 26,372.25 191,697.33 (66.7)
 • Total 22,954.00 206,087.00 3,575.38 54,819.30 287,435.68 (100)
ChD
 • Males - - 6,180.19 19,225.19 25,405.38 (44.9)
 • Females - - 11,807.21 19,348.49 31,155.70 (55.1)
 • Total - - 17,987.40 38,573.68 56,561.08 (100)
s
 • Males - 50,399.00 328.07 8,656.35 59,383.42 (38.2)
 • Females - 93,812.00 423.70 1,641.60 95,877.30 (61.8)
 • Total - 144,211.00 751.77 10,297.95 155,260.72 (100)
gD
 • Males - - - 1,560.20 1,560.20 (58.3)
 • Females - - - 1,114.80 1,114.80 (41.7)
 • Total - - - 2,675.00 2,675.00 (100)
BC
 • Males 0.00 - 0.00 0.00 0.00(0)
 • Females 72,355.00 - 27.34 40,174.64 112,556.98 (100)
 • Total 72,355.00 - 27.34 40,174.64 112,556.98 (100)
CC
 • Males - - 0.00 7,135.54 7,135.54(60.6)
 • Females - - 2,859.76 1,777.30 4,637.06 (39.4)
 • Total - - 2,859.76 8,912.84 11,772.60 (100)
Oa
 • Males - 133,233.00 1,225.87 163.08 134,621.95 (38.0)
 • Females - 216,566.00 0.00 2,845.27 219,411.27 (62.0)
 • Total - 349,799.00 1,225.87 3,008.35 354,033.22 (100)
hC
 • Males - - 13.67 0.00 13.67 (6.2)
 • Females - - 0.00 207.52 207.52(93.8)
 • Total - - 13.67 207.52 221.19 (100)
economic burden
 • Males 0.00 832,332.00 21,168.42 101,752.55 955,252.97 (49.4)
 • Females 95,309.00 735,526.00 18,730.68 127,422.01 976,987.69 (50.6)
 • Total 95,309.00 1,567,858.00 39,899.10 229,175.56 1,932,240.66 (100)
Table iV. Breakdown of the total indirect costs of the diseases studied by gender (US$)
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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70% of direct cost was accrued by females 
(Table II and V). Women were not found to 
be statistically associated with greater direct 
costs (p = 0. 30; CI = 95%). Total indirect 
of the cost of all conditions studied except 
coronary heart disease (Table V). Total direct 
cost of the total burden of disease was US$ 
3,740,377.02 (65.9% of total cost). About 
red for both genders, this cost was estimated 
from the YPLL, and could only be compu-
ted for women because the mortality obser-
ved for males occurred beyond the age of 65 
years. The diseases responsible for this cost 
were breast cancer at US$ 72,355.00 (75.9% 
cost of premature mortality) and hyperten-
sion at US$ 22,954.00 (24.1% cost of prema-
ture mortality) (Table IV).
Permanent disability
The total discounted cost of permanent disa-
bility was based on 38 patients and accrued a 
cost of US$ 1,908,176.00 (28% of total cost 
and 81% of total indirect cost). The comorbi-
dities responsible for permanent disabilities 
were diabetes mellitus, hypertension, stro-
ke and osteoarthritis, accruing discounted 
costs of US$ 867,761.00, US$ 206,087.00, 
US$144,211.00, and US$ 349,799.00, re-
spectively (Table IV).
Cost of temporary disability
The total discounted cost of temporary di-
sability in patients under 65 years who were 
not permanently disabled amounted to US$ 
39,899.10 in lost productivity. Fifty-three 
percent of this loss was as a result of tempo-
rary disability in men. Temporary disability 
was responsible for 2% of the indirect cost 
and 0.7% of the total cost of the diseases stu-
died (Table IV).
Coronary heart diseases accrued the greatest 
cost due to temporary disability followed by 
diabetes, hypertension, and colon cancer at 
US$ 17,987.40 (45%), US$ 13,457.91 (34%), 
US$ 3,575.38 (9%), and US$ 2,859.76 (9%), 
respectively (Table IV).
Cost of absenteeism
The total cost of absentee days was US$ 
229,175.56. Women were responsible for 
55.5% of overall losses due to absenteeism. 
The diseases that contributed the most to this 
cost were diabetes mellitus, hypertension, 
breast cancer and coronary heart disease at 
US$ 70,505.28 (31%), US$ 54,819.30 (24%), 
US$ 40,174.64 (18%), and US$ 38,573.68 
(17%), respectively (Table IV).
Overall costs
The sum of the costs attributable to the di-
seases studied was US$ 5,672,617.68. The 
four main contributors were diabetes mellitus 
(47.0%), breast cancer (18.8%), hypertension 
(10.0%), and coronary heart disease (9.6%). 
Female patients were responsible for 63.3% 
of the overall costs attributable to the dise-
ases covered. However, being a woman was 
not found to be statistically associated with 
greater overall costs (p = 0.44; CI = 95%). 
Female patients also accrued more than half 
Disease
indirect cost (Us$)
Premature 
mortality
Permanent 
disability
Temporary 
disability
absenteeism Total [Us$ (%)]
DM
 • Males - 583,331.00 11,498.32 36,565.14 631,394.46 (66.3)
 • Females - 284,430.00 1,959.59 33,940.14 320,329.73 (33.7)
 • Total - 867,761.00 13,457.91 70,505.28 951,724.19 (100)
hTn
 • Males 0.00 65,369.00 1,922.30 28,447.05 95,738.35 (33.3)
 • Females 22,954.00 140,718.00 1,653.08 26,372.25 191,697.33 (66.7)
 • Total 22,954.00 206,087.00 3,575.38 54,819.30 287,435.68 (100)
ChD
 • Males - - 6,180.19 19,225.19 25,405.38 (44.9)
 • Females - - 11,807.21 19,348.49 31,155.70 (55.1)
 • Total - - 17,987.40 38,573.68 56,561.08 (100)
s
 • Males - 50,399.00 328.07 8,656.35 59,383.42 (38.2)
 • Females - 93,812.00 423.70 1,641.60 95,877.30 (61.8)
 • Total - 144,211.00 751.77 10,297.95 155,260.72 (100)
gD
 • Males - - - 1,560.20 1,560.20 (58.3)
 • Females - - - 1,114.80 1,114.80 (41.7)
 • Total - - - 2,675.00 2,675.00 (100)
BC
 • Males 0.00 - 0.00 0.00 0.00(0)
 • Females 72,355.00 - 27.34 40,174.64 112,556.98 (100)
 • Total 72,355.00 - 27.34 40,174.64 112,556.98 (100)
CC
 • Males - - 0.00 7,135.54 7,135.54(60.6)
 • Females - - 2,859.76 1,777.30 4,637.06 (39.4)
 • Total - - 2,859.76 8,912.84 11,772.60 (100)
Oa
 • Males - 133,233.00 1,225.87 163.08 134,621.95 (38.0)
 • Females - 216,566.00 0.00 2,845.27 219,411.27 (62.0)
 • Total - 349,799.00 1,225.87 3,008.35 354,033.22 (100)
hC
 • Males - - 13.67 0.00 13.67 (6.2)
 • Females - - 0.00 207.52 207.52(93.8)
 • Total - - 13.67 207.52 221.19 (100)
economic burden
 • Males 0.00 832,332.00 21,168.42 101,752.55 955,252.97 (49.4)
 • Females 95,309.00 735,526.00 18,730.68 127,422.01 976,987.69 (50.6)
 • Total 95,309.00 1,567,858.00 39,899.10 229,175.56 1,932,240.66 (100)
Table iV. Breakdown of the total indirect costs of the diseases studied by gender (US$)
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, 
HTN = hypertension, OA = osteoarthritis, S = Stroke
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cost amounted to US$ 1,932,240.66 (34.1% 
of total cost). About 51% of indirect cost was 
accrued by females (Table IV and V). When 
the cost of breast cancer was removed from 
direct and indirect costs, females accrued 
59.7% and 47.5% of the total direct and indi-
rect costs, respectively.
Total costs attributable to obesity
In order to arrive at the costs attributable 
to obesity, the population attributable risk 
(PAR) for each disease due to obesity was 
calculated as outlined in the methodology 
(Table I). The resulting values were then ap-
plied to the cost of each disease.
The overall costs attributable to obesi-
ty for males and females were estimated at 
US$ 271,921.28 and US$ 885,251.61, re-
spectively, giving a total estimate of US$ 
1,157,172.89. This figure does not include 
premature mortality since the level of prema-
ture mortality was very low and perhaps did 
not reflect the true mortality rate of the pa-
tients. Therefore, males and females contri-
buted 23.5% and 76.5%, respectively to the 
cost of obesity (Table VI). Women were not 
found to be statistically associated with grea-
ter obesity costs (p = 0.16; CI = 95%). When 
the cost of breast cancer was removed from 
the cost of obesity, females accrued 74.6% of 
the cost (p = 0.23; CI = 95%). Also, when 
both breast cancer and colon cancer costs 
were removed from the cost of obesity, fe-
males accrued 74.6% of the cost (p = 0.23; 
CI = 95%).
dIscussIon
This is a cost-of-illness study in which data 
analysed were collected from the hospital re-
cords of 554 patients who were treated at the 
University Hospital of the West Indies during 
2006 for obesity-related diseases, thereby ar-
riving at an estimate of the direct and indirect 
costs of obesity. This method is considered 
more accurate than using prevalence data for 
the estimation of cost because, in such me-
thodologies, all patients with the same mala-
dy are treated as a homogenous group while 
patients with similar diagnoses may have 
vastly different treatment experiences and 
costs. The present study did not include the 
costs of pain and suffering [54], or presen-
teeism (reduced performance while at work 
due to ill health) [55].
This study estimated the economic burden 
attributable to the nine diseases of interest to 
be US$ 5,672,617.68 for the patients studied. 
The three main contributors were diabetes 
mellitus, breast cancer and hypertension, 
with female patients being responsible for 
63.3% of the overall costs. However, there is 
a potential for bias towards females due to 
the failure to include a principal male cancer 
(e.g., prostate cancer), where there is growing 
evidence of a relationship with obesity [56]. 
Disease
Direct costs 
(Us$)
indirect costs 
(Us$)
Total costs 
[Us$ (%)]
DM
 • Males 642,953.41 631,394.46 1,274,347.87 (47.8)
 • Females 1,071,660.86 320,329.73 1,391,990.59 (52.2)
 • Total 1,714,614.27 951,724.19 2,666,338.46 (100)
hTn
 • Males 129,234.77 95,738.35 224,973.12 (39.5)
 • Females 153,414.31 191,697.33 345,111.64 (60.5)
 • Total 282,649.08 287,435.68 570,084.76 (100)
ChD
 • Males 253,452.74 25,405.38 278,858.12 (51.3)
 • Females 233,323.08 31,155.70 264,478.78 (48.7)
 • Total 486,775.82 56,561.08 543,336.90 (100)
s
 • Males 38,068.81 59,383.42 97,452.23 (41.0)
 • Females 44,400.12 95,877.30 140,277.42 (59.0)
 • Total 82,468.93 155,260.72 237,729.65 (100)
gD
 • Males 764.25 1,560.20 2,324.45(17.2)
 • Females 10,070.09 1,114.80 11,184.89(82.8)
 • Total 10,834.34 2,675.00 13,509.34 (100)
BC
 • Males 0.00 0.00 0.00 (0)
 • Females 952,998.65 112,556.98 1,065,555.63 (100)
 • Total 952,998.65 112,556.98 1,065,555.63 (100)
CC
 • Males 19,163.36 7,135.54 26,298.90 (37.8)
 • Females 38,635.57 4,637.06 43,272.63 (62.2)
 • Total 57,798.93 11,772.60 69,571.53 (100)
Oa
 • Males 19,682.62 134,621.95 154,304.57 (33.6)
 • Females 85,153.48 219,411.27 304,564.75 (66.4)
 • Total 104,836.10 354,033.22 458,869.32 (100)
hC
 • Males 20,813.10 13.67 20,826.77 (43.7)
 • Females 26,587.80 207.52 26,795.32(56.3)
 • Total 47,400.90 221.19 47,622.09 (100)
economic burden
 • Males 1,124,133.06 955,252.97 2,079,386.03 (36.7)
 • Females 2,616,243.96 976,987.69 3,593,231.65 (63.3)
 • Total 3,740,377.02 1,932,240.66 5,672,617.68 (100)
Table V. Total cost of care for the diseases studied by gender (US$)
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes 
Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, HTN = hypertension, 
OA = osteoarthritis, S = Stroke
Diseases
Cost (Us$)
Males Females Total [Us$ (%)]
DM 140,178.27 417,597.18 557,775.44 (48.2)
HTN 31,496.24 138,044.66 169,540.90 (14.7)
CHD 13,942.91 29,092.67 43,035.58 (3.7)
S 8,770.70 29,458.26 38,228.96 (3.2)
GD 139.46 5,256.89 5,396.35 (0.5)
BC - 85,244.45 85,244.45 (7.4)
CC 4,207.82 15,145.42 19,353.24 (1.7)
OA 69,437.06 152,282.37 221,719.43 (19.2)
HC 3,748.82 13,129.71 16,878.53 (1.4)
Economic 
burden 
[US$ (%)]
271,921.28 (23.5) 885,251.61 (76.5) 1,157,172.89 (100)
Table Vi. Cost attributable to obesity for the diseases studied
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes 
Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, HTN = hypertension, 
OA = osteoarthritis, S = Stroke
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Female patients also accrued more than half 
of the cost of all diseases studied except for 
coronary heart disease. This is contrary to 
expectation given that females accounted for 
60% of the cases studied. The higher direct 
cost for female patients is due to their uni-
que presentation in breast cancers which also 
bore the highest direct cost.
Total direct and indirect costs attributable to 
the nine diseases of interest were estimated 
at US$ 3,740,377.02 and US $1,932,240.66, 
respectively for men and women. Women ac-
crued 70% of direct costs and 51% of indirect 
costs but also represented 60% of the study 
population. The total per capita direct costs 
for men and women were US$ 5,109.70 and 
US $7,833.07, respectively. The total per ca-
pita indirect costs for men and women were 
US$ 4,342.06 and US$ 2,925.11, respecti-
vely. Given the higher prevalence of obesity 
among Jamaican women [5], they seemed 
to have been managing their conditions bet-
ter than the men, with lower indirect costs. 
Their conditions could have been more easily 
managed with drugs while the men needed 
more diagnostic and treatment interventions. 
When breast cancer cases were excluded, 
women accrued 60% of direct and 48% of 
indirect costs. The greatest contributors to di-
rect cost were prescription drugs followed by 
treatment services at US$ 2,245,245.10 and 
US$ 1,109,142.18, respectively. The greatest 
contributors to indirect cost were permanent 
disability followed by the absenteeism at 
US$ 1,567,858.00 and US$ 229,175.56, re-
spectively.
The overall cost of obesity was estimated at 
US$ 1,157,172.89 (20% of total overall cost 
for the diseases studied), with females con-
tributing 77% of the overall cost of obesity. 
Excluding breast cancer, the female contribu-
tion to the cost of obesity falls to 75%. This 
estimate did not include premature mortality 
due to the inadequacy of data: although mor-
tality occurred for both genders, the mortality 
observed for males occurred beyond the age 
of 65 years and thus could not be included in 
the calculation of YPLL. Thus, YPLL could 
only be computed for women. For all dise-
ases, females contributed more than 50% to 
the cost of obesity. In a previous study of 
8 diseases (not including breast and colon 
cancer), females contributed to 55% of the 
overall cost of obesity [57], which is lower 
compared to our data when these two cancers 
are excluded.
Diabetes contributed the most to the cost of 
obesity at US$ 557,775.44 (48%), followed 
by osteoarthritis, hypertension, and bre-
ast cancer at US$ 221,719.43 (19%), US$ 
169,540.90 (15%), and US$ 85,244.45 (7%), 
respectively. The PAR of obesity in diabetes 
is not disproportionate when compared to 
the PAR of obesity in the other diseases. In 
a study that estimated direct costs of obesity 
for a group of diseases that did not include 
osteoarthritis, the 3 largest contributors to 
the costs were hypertension, type 2 diabetes 
mellitus and coronary artery disease [51]. In 
another study that estimated costs of obesity 
for a group of diseases (osteoarthritis exclu-
ded), coronary artery disease, type 2 diabetes 
mellitus and hypertension were among the 
4 largest contributors to the costs [38]. The-
refore, the results are comparable with type 
2 diabetes mellitus and hypertension being 
among the top 4 contributors.
Cardiovascular disease has been predicted 
to be the leading cause of death and disabi-
lity worldwide by 2020 [58]. However, the 
leading cause of permanent disability in this 
study was diabetes mellitus. In this study, the 
two contributors to mortality were hyper-
tension and breast cancer, with an estimated 
cost of US$ 22,954.00 and US$ 72,355.00 
respectively. Mortality is however projected 
to increase dramatically from ischemic heart 
disease in developing countries by 2020 [59]. 
In previous studies, cerebrovascular diseases, 
heart diseases, hypertensive diseases, diabe-
tes mellitus, and malignant neoplasms have 
been found to be among the ten leading cau-
ses of death in Jamaica [36,60].
conclusIons
This study has shown the high cost of 
CNCDs, with diabetes accruing the highest 
cost overall as well as the highest cost at-
tributable to obesity. On a per capita basis, 
59.7% and 47.5% of the total direct and indi-
rect costs, respectively.
Total costs attributable to obesity
In order to arrive at the costs attributable 
to obesity, the population attributable risk 
(PAR) for each disease due to obesity was 
calculated as outlined in the methodology 
(Table I). The resulting values were then ap-
plied to the cost of each disease.
The overall costs attributable to obesi-
ty for males and females were estimated at 
US$ 271,921.28 and US$ 885,251.61, re-
spectively, giving a total estimate of US$ 
1,157,172.89. This figure does not include 
premature mortality since the level of prema-
ture mortality was very low and perhaps did 
not reflect the true mortality rate of the pa-
tients. Therefore, males and females contri-
buted 23.5% and 76.5%, respectively to the 
cost of obesity (Table VI). Women were not 
found to be statistically associated with grea-
ter obesity costs (p = 0.16; CI = 95%). When 
the cost of breast cancer was removed from 
the cost of obesity, females accrued 74.6% of 
the cost (p = 0.23; CI = 95%). Also, when 
both breast cancer and colon cancer costs 
were removed from the cost of obesity, fe-
males accrued 74.6% of the cost (p = 0.23; 
CI = 95%).
dIscussIon
This is a cost-of-illness study in which data 
analysed were collected from the hospital re-
cords of 554 patients who were treated at the 
University Hospital of the West Indies during 
2006 for obesity-related diseases, thereby ar-
riving at an estimate of the direct and indirect 
costs of obesity. This method is considered 
more accurate than using prevalence data for 
the estimation of cost because, in such me-
thodologies, all patients with the same mala-
dy are treated as a homogenous group while 
patients with similar diagnoses may have 
vastly different treatment experiences and 
costs. The present study did not include the 
costs of pain and suffering [54], or presen-
teeism (reduced performance while at work 
due to ill health) [55].
This study estimated the economic burden 
attributable to the nine diseases of interest to 
be US$ 5,672,617.68 for the patients studied. 
The three main contributors were diabetes 
mellitus, breast cancer and hypertension, 
with female patients being responsible for 
63.3% of the overall costs. However, there is 
a potential for bias towards females due to 
the failure to include a principal male cancer 
(e.g., prostate cancer), where there is growing 
evidence of a relationship with obesity [56]. 
Disease
Direct costs 
(Us$)
indirect costs 
(Us$)
Total costs 
[Us$ (%)]
DM
 • Males 642,953.41 631,394.46 1,274,347.87 (47.8)
 • Females 1,071,660.86 320,329.73 1,391,990.59 (52.2)
 • Total 1,714,614.27 951,724.19 2,666,338.46 (100)
hTn
 • Males 129,234.77 95,738.35 224,973.12 (39.5)
 • Females 153,414.31 191,697.33 345,111.64 (60.5)
 • Total 282,649.08 287,435.68 570,084.76 (100)
ChD
 • Males 253,452.74 25,405.38 278,858.12 (51.3)
 • Females 233,323.08 31,155.70 264,478.78 (48.7)
 • Total 486,775.82 56,561.08 543,336.90 (100)
s
 • Males 38,068.81 59,383.42 97,452.23 (41.0)
 • Females 44,400.12 95,877.30 140,277.42 (59.0)
 • Total 82,468.93 155,260.72 237,729.65 (100)
gD
 • Males 764.25 1,560.20 2,324.45(17.2)
 • Females 10,070.09 1,114.80 11,184.89(82.8)
 • Total 10,834.34 2,675.00 13,509.34 (100)
BC
 • Males 0.00 0.00 0.00 (0)
 • Females 952,998.65 112,556.98 1,065,555.63 (100)
 • Total 952,998.65 112,556.98 1,065,555.63 (100)
CC
 • Males 19,163.36 7,135.54 26,298.90 (37.8)
 • Females 38,635.57 4,637.06 43,272.63 (62.2)
 • Total 57,798.93 11,772.60 69,571.53 (100)
Oa
 • Males 19,682.62 134,621.95 154,304.57 (33.6)
 • Females 85,153.48 219,411.27 304,564.75 (66.4)
 • Total 104,836.10 354,033.22 458,869.32 (100)
hC
 • Males 20,813.10 13.67 20,826.77 (43.7)
 • Females 26,587.80 207.52 26,795.32(56.3)
 • Total 47,400.90 221.19 47,622.09 (100)
economic burden
 • Males 1,124,133.06 955,252.97 2,079,386.03 (36.7)
 • Females 2,616,243.96 976,987.69 3,593,231.65 (63.3)
 • Total 3,740,377.02 1,932,240.66 5,672,617.68 (100)
Table V. Total cost of care for the diseases studied by gender (US$)
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes 
Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, HTN = hypertension, 
OA = osteoarthritis, S = Stroke
Diseases
Cost (Us$)
Males Females Total [Us$ (%)]
DM 140,178.27 417,597.18 557,775.44 (48.2)
HTN 31,496.24 138,044.66 169,540.90 (14.7)
CHD 13,942.91 29,092.67 43,035.58 (3.7)
S 8,770.70 29,458.26 38,228.96 (3.2)
GD 139.46 5,256.89 5,396.35 (0.5)
BC - 85,244.45 85,244.45 (7.4)
CC 4,207.82 15,145.42 19,353.24 (1.7)
OA 69,437.06 152,282.37 221,719.43 (19.2)
HC 3,748.82 13,129.71 16,878.53 (1.4)
Economic 
burden 
[US$ (%)]
271,921.28 (23.5) 885,251.61 (76.5) 1,157,172.89 (100)
Table Vi. Cost attributable to obesity for the diseases studied
BC =Breast Cancer, CC = Colon Cancer, CHD = Coronary Heart Disease, DM = Diabetes 
Mellitus, GD = Gallbladder Disease, HC = High Cholesterol, HTN = hypertension, 
OA = osteoarthritis, S = Stroke
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females accrued greater costs of illness for 
gallbladder disease (US$ 33.49 vs. US$ 
10.57 about three times that of the males) and 
osteoarthritis (US$ 911.87 vs. US$ 701.38). 
On a per capita basis, males accrued higher 
costs of illness for diabetes mellitus (US$ 
5,792.49 vs. US$ 4,167.64), coronary heart 
disease (US$ 1,267.54 vs. US$ 791.85) and 
high cholesterol (US$ 94.67 vs. US$ 80.23). 
On a per capita basis, males and females ac-
crued similar costs of illness for hypertension 
(US$ 1,022.61 vs. US$ 1,033.27), stroke 
(US$ 442.96 vs. US$ 419.99), and colon can-
cer (US$ 119.54 vs. US$ 129.56). Overall, on 
a per capita basis, males and females accrued 
similar costs of illness (US$ 9,451.75 vs. 
US$ 10,758.18).
Obesity was responsible for 20.4% of total 
overall cost of the diseases studied. With 
respect to the cost of illness due to obesity, 
on a per capita basis, females accrued gre-
ater costs of illness for all of the diseases 
studied: diabetes mellitus (US$ 1,250.29 vs. 
US$ 637.17, twice than males), hypertension 
(US$ 413.31 vs. US$ 143.16, about three ti-
mes than males), coronary heart disease (US$ 
87.10 vs. US$ 63.38), stroke (US$ 88.20 vs. 
US$ 39.87, more than twice than males), 
gallbladder disease (US$ 15.74 vs. US$ 0.63, 
twenty-five times than males), colon cancer 
(US$ 45.35 vs. US$ 19.13, more than twi-
ce than males), osteoarthritis (US$ 455.94 
vs. US$ 315.62), and hypercholesterolemia 
(US$ 39.31 vs. US$ 17.04, more than twi-
ce than males). In addition, females accrued 
77% of the cost of illness due to obesity with 
them accruing a higher per capita cost than 
males (US$ 2,650.45 vs. US$ 1,236.01 twice 
than males).
This study showed that although Jamai-
ca is not an affluent country, obesity and 
its comorbidities are important sources of 
economic burden. This is therefore further 
argument that chronic non-communicable 
diseases are not necessarily diseases of af-
fluence. In addition, this study indicated that 
although Jamaica is in a public health tran-
sition, obesity is already showing a strong 
impact on medical and economic costs to 
the country. In general, policies to control 
and prevent CNCDs should seek to impro-
ve lifestyle behavior activities (diet and 
physical activity) of both men and women, 
if these indicators are to improve. Jamaica 
could include in its planning for the future, 
the training of health personnel (particularly 
physicians, dieticians and nutritionists) in 
the management and prevention of obesity. 
As the demographic transition continues and 
the population ages, the economic costs will 
become unsurmountable if efforts to arrest 
this trend do not begin.
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